Consensus statement on directly observed therapies for tuberculosis;Documento de consenso sobre tratamientos directamente observados en tuberculosis

Medicina Clinica

Volumn 115, Issue 19, 2000, Pages 749-757

  Cayla, J A ^a  

^a Institut Municipal de Salut Publica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CLARITHROMYCIN; ETHAMBUTOL; HYDRAZINE; ISONIAZID; METHADONE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN;

CONFERENCE PAPER; HUMAN; LIVER TOXICITY; PATIENT COMPLIANCE; PATIENT EDUCATION; SHORT COURSE THERAPY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULOSIS;

EID: 0034597938     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71680-0     Document Type: Conference Paper

References (111)

1. Treatment of tuberculosis
2. Consenso Nacional para el control de la Tuberculosis en España
3. Epidemiological trends of tuberculosis in Spain from 1988 to 1992
4. Incidence of tuberculosis in Spain: Preliminary results from the Multicenter Project for TB Research (MPTR)
5. Area de Tuberculosis e Infecciones respiratorias (TIR) de la Sociedad Española de Neumologia y Cirugia Toracica (SEPAR) y Grupo de SIDA (GESIDA) de la Sociedad Española de Enferrnedades Infecciosas y Microbiologia Clinica (SEIMC). Documento de consenso sobre la prevencion y control de la Tuberculosis en España
6. Compliance with tuberculosis therapy
7. USPHS Tuberculosis Short Course Chemotherapy Trial 21: Effectiveness, toxicity, and acceptability. The report of final results
8. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and decline of tuberculosis control programs
9. Estructura organizativa del tratamiento de la tuberculosis en un pais endemico
10. Movement of tuberculosis patients and the failure to complete antituberculosis treatment
11. Lancet Conference: The challenge tuberculosis: Statements on global control and prevention
12. Grupo de Estudio de Contactos de la Unidad de Investigacion en Tuberculosis de Barcelona (UITB) Documento de consenso sobre el estudio de contactos en los pacientes tuberculosos
13. Directly observed therapy for tuberculosis: History of an idea
14. Directly observed treatment of tuberculosis. We can't afford no to try it
15. Studies on the treatment of tuberculosis undertaken by British Medical research Council Tuberculosis unit. 1946-1986, with relevant subsequent publications
16. The Origins of DOT
17. The origins of DOTS
18. Ontenos y normas generales sobre quimoterapia antituberculosa. Papel del hospital en el tratamiento del enfermo tuberculoso. Parte I
19. Towards elimination of tuberculosis in a low income country the experience of Cuba. 1962-1997
20. Directly Observed Theraphy in New York City. History. Implementation results and challenges
21. Directly observed therapy and treatment adherence
22. Prospects for worldwide tuberculosis control under WHO DOTS strategy. Directly observed short-course therapy
23. Progress in global tuberculosis control 1995-1996 with emphasis on 22 high incidence countries
24. Eleven years of of community-based directly observed therapy for tuberculosis
25. Evolución de la tuberculosis en Barcelona (1987-1995). Influencia del virus de la inmunodeficiencia humana y de las medidas de control
26. Cost-effectiveness of directly observed therapy versus self-administered theraphy for tuberculosis
27. Cost-comparison of different management policies for tuberculosis patients in Italy. AlPO TB Study Group
28. Chin DP Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default
29. Treatment costs of directly observed therapy arid traditional therapy for Mycobacterium tuberculosis: A comparative analysis
30. A behavioral medicine perspective on adherence to long-term medical regimes
31. Approaches to improving adherence to antituberculosis therapy
32. Compliance with anti-tuberculosis chemotherapy in developing countries
33. Terapia de observacion directa de la tuberculosis
34. Resultados e impacto epidemiologico de una unidad de tratamiento directamente observado de la tuberculosis
35. Compliance with tuberculosis therapy
36. Evaluation of a social health intervention among homless tuberculosis patients
37. Beyon four drugs. Public health policy and the treatment of the individual patient with tuberculosis
38. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis
39. Functional evaluation the Barthel Index
40. Interventions for promoting adherence to tuberculosis treatment (Cochrane Review)
41. Manejo de la tuberculosis en Europa
42. Control y seguimiento del enfermo tuberculoso
43. Adherencia a la quirnioprofilaxis antituberculosa Empleo de tecnicas de marketing sanitario y educacion para la salud en el medio penitenciano
44. The correctional facility challenge to public health efforts to control tuberculosis in the United States
45. La adhesion al tratamiento antirretrovral. Una perspectiva global del problema y posibles soluciones
46. Enhancing patient compliance with tuberculosis therapy
47. When tuberculosis treatment fails, a social behavioural account of patient adherence
48. Compliance and supervision of chemotherapy of tuberculosis
49. The impact of intensified supervisory activities on tuberculosis treatment
50. Tuberculosis screening and compliance with return for skin test reading among active drug users
51. A patient education program to improve adherence rates with antituberculosis drug regimens
52. Short course chemotherapy: A controlled study of indirect defaulter retrieval method
53. Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referraI
54. Evaluation of the efficacy of health education on the compliance with antituberculous chemoprophylaxis in school children. A randomized clinical trial
55. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand
56. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis
57. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
58. Interacciones entre los antirretrovirales y los larmacos utilizados en el tratamiento de la tuberculosis
59. Interacciones de los farmacos antirretrovirales
60. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
61. The treatment of tuberculosis in HIV-infected persons
62. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antiretroviral en pacientes adultos inlectados por el VIH en el año 2000
63. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons
64. Pulmonary tuberculosis in HlV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months
65. Relapse of tubercuIosis alter treatment in human inmunodeficiency virus-infected patients
66. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
67. Tuberculosis Fact Shet 2g: Management and treatment of active tuberculosis in HIV-infected persons
68. Effect of tuberculosis therapy on nevirapine trough plasma concentrations
69. Targeted tuberculin testing and treatment of latent tuberculosis infection
70. Recomendaciones SEPAR
71. Control de la tuberculosis en relacion con la epidemia de infeccion por VIH/SIDA. Ministerio de Sanidad y Consumo
72. Hepatotoxicity associated with isoniazid preventive therapy. A 7 year survey from public health tubercuIosis clinic
73. Eleven years of community-based directly observed therapy for tuberculosis
74. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
75. Randomised trial of iosniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
76. Rifampicin and pyrazinamide vs isoniazic for prevention of tuberculosis in HIV-infected persons: An international randomized trial
77. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
78. Rifampin preventive therapy for tuberculosis infection: Experience with 157 adolescents
79. Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance
80. Tratamiento de la tuberculosis: Cumplimiento abandono y tratamientos supervisados
81. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before arid after release
82. Metadona mas antituberculosos
83. Tratamiento observado directamente de la tuberculosis en ADVP. Meladona mas tuberculostaticos
84. Tratamiento directamente observado en una unidad de tuberculosis
85. When tuberculosis treatment fails. A social behavioural account of patient adherence
86. Tratamiento de la infeccion tuberculosa en poblacion reclusa. Prevalencia inslantanea en una prision provincial
87. Un programa de promotion de salud en el medion penitenciano
88. Quimioprofilaxis secundaria de tuberculosis en coinfectados TBC/VIH con dos farmacos durante ires meses
89. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a working group of the World Health Organisation (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients